Molecular Biology of Neurodegenerative Diseases: Visions for the Future
Specificaties
Gebonden, blz.
|
Engels
Elsevier Science |
2019
ISBN13: 9780128178744
Rubricering
Onderdeel van serie
Progress in Molecular Biology and Translational Science
Levertijd ongeveer 9 werkdagen
Gratis verzonden
Samenvatting
Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Volume 168 in the Progress in Molecular Biology and Translational Science series, provides the most topical, informative and exciting monographs available on a wide variety of research topics. The series includes in-depth knowledge on the molecular biological aspects of organismal physiology, with this release including chapters on Alzheimer's disease, Prion-like propagation of alpha-synuclein, What - if anything - can we learn about neurodegenerative diseases from yeast?, Mitochondrial rejuvenation and replacement as a novel strategy for treatment of age-related neurodegenerative diseases, Propagation and removal of cerebral amyloid angiopathy, and much more.
Specificaties
Inhoudsopgave
<p>Section I: TARGETTING AD</p> <p>1. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings</p> <p>Kaj Blennow and Henrik Zetterberg</p> <p>2. Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis</p> <p>Minako Hoshi</p> <p>3. Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid β-protein</p> <p>Ariel J. Kuhn and Jevgenij A. Raskatov</p> <p>Section II: ETIOLOGY OF AD</p> <p>4. In search of pathogenic amyloid β-peptide in familial Alzheimer's disease</p> <p>Michael S. Wolfe</p> <p>5. Biology of splicing in Alzheimer's disease research</p> <p>Kenichi Nagata, Takashi Saito, Takaomi C. Saido and Takashi Morihara</p> <p>6. Acquired cerebral amyloid angiopathy: An emerging concept</p> <p>Masahito Yamada, Tsuyoshi Hamaguchi and Kenji Sakai</p> <p>Section III: NEUROIMMUNOLOGY OF AD</p> <p>7. Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease</p> <p>Goran Šimić, Ena Španić, Lea Langer Horvat and Patrick R. Hof</p> <p>8. Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease</p> <p>Susan Westfall, Umar Iqbal, Maria Sebastian and Giulio Maria Pasinetti</p> <p>9. Neuroimmune interactions in Alzheimer’s disease—New frontier with old challenges?</p> <p>Stefan Prokop, Virginia M.Y. Lee and John Q. Trojanowski</p> <p>Section IV: AD THERAPY</p> <p>10. Alzheimer's therapy development: A few points to consider</p> <p>Einar M. Sigurdsson</p> <p>11. The next steps in curing Alzheimer's disease</p> <p>Fred W. van Leeuwen</p> <p>12. Future horizons in Alzheimer's disease research</p> <p>Thomas Wisniewski and Eleanor Drummond</p> <p>13. Why delay in effective treatment for Alzheimer's disease and related conditions</p> <p>Khalid Iqbal, Fei Liu, ChengXin Gong, Chunling Dai and Wen Hu</p> <p>14. Restoring synaptic function through multimodal therapeutics</p> <p>Raul Loera-Valencia, Muhammad-Al-Mustafa Ismail, Per Nilsson and Bengt Winblad</p> <p>15. Disease-modifying therapy for proteinopathies: Can the exception become the rule?</p> <p>Gal Bitan</p> <p>16. Combination therapy for Alzheimer’s disease and related dementias</p> <p>Martin M. Bednar</p> <p>Section V: ALPHA-SYNUCLEINOPATHIES</p> <p>17. Can infections trigger alpha-synucleinopathies?</p> <p>Christopher T. Tulisiak, Gabriela Mercado, Wouter Peelaerts, Lena Brundin and Patrik Brundin</p> <p>18. Prion-like propagation of α-synuclein in neurodegenerative diseases</p> <p>Airi Tarutani and Masato Hasegawa</p> <p>Section VI: MODEL SYSTEMS</p> <p>19. Yeast models of neurodegenerative diseases</p> <p>Mick F. Tuite</p>